Corrected on Feb 25, 2022.

Source: the publisher, via Crossref · checked Oct 18, 2026 · Read the notice

Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives

Elidie Beard, Sylvain Lengacher, Sara Dias and 2 more

Frontiers in Physiology · 2022 · Review · CC BY

doi:10.3389/fphys.2021.825816

Abstract

Astrocytes play key roles in the regulation of brain energy metabolism, which has a major impact on brain functions, including memory, neuroprotection, resistance to oxidative stress and homeostatic tone. Energy demands of the brain are very large, as they continuously account for 20–25% of the whole body’s energy consumption. Energy supply of the brain is tightly linked to neuronal activity, providing the origin of the signals detected by the widely used functional brain imaging techniques such as functional magnetic resonance imaging and positron emission tomography. In particular, neuroenergetic coupling is regulated by astrocytes through glutamate uptake that triggers astrocytic aerobic glycolysis and leads to glucose uptake and lactate release, a mechanism known as the Astrocyte Neuron Lactate Shuttle. Other neurotransmitters such as noradrenaline and Vasoactive Intestinal Peptide mobilize glycogen, the reserve for glucose exclusively localized in astrocytes, also resulting in lactate release. Lactate is then transferred to neurons where it is used, after conversion to pyruvate, as a rapid energy substrate, and also as a signal that modulates neuronal excitability, homeostasis, and the expression of survival and plasticity genes. Importantly, glycolysis in astrocytes and more generally cerebral glucose metabolism progressively deteriorate in aging and age-associated neurodegenerative diseases such as Alzheimer’s disease. This decreased glycolysis actually represents a common feature of several neurological pathologies. Here, we review the critical role of astrocytes in the regulation of brain energy metabolism, and how dysregulation of astrocyte-mediated metabolic pathways is involved in brain hypometabolism. Further, we summarize recent efforts at preclinical and clinical stages to target brain hypometabolism for the development of new therapeutic interventions in age-related neurodegenerative diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The brain requires high amounts of energy to function. As a result, 20–25% of the energy consumed by the human body is dedicated to cerebral functions, although the brain only represents 2% of the total body mass. Maintenance and restoration of neuronal ion gradients and synaptic transmission, as well as uptake and recycling of neurotransmitters are the major contributors to these energy demands. Glucose is the main energy substrate in the adult brain. However, other sources of energy can be used under particular circumstances, such as ketone bodies that are consumed during development and fasting, and lactate that can be preferentially used during periods of intense physical activity. Importantly, when plasma lactate concentrations rise, central nervous system (CNS) lactate levels also increase, which is correlated with decreased glucose uptake, and indicating a preferential utilization of lactate over glucose as brain energy source.

2Several neurodegenerative diseases linked to aging are characterized by a decrease in the consumption of energy by the brain in specific regions. These include, among others, Alzheimer’s disease (AD), Parkinson’s disease (PD), Frontotemporal dementia (FTD), Amyotrophic lateral sclerosis (ALS), depression and certain neurodevelopmental disorders. Hypometabolism also occurs in physiological aging, a fact that may participate in the vulnerability of the nervous system to pathological states of aging. Decreased energy availability for neurons results in neurodegeneration, cognitive impairment, as well as abnormalities in neuronal function and excitability. Astrocytes, a type of glial cells in the brain, support essential functions such as maintenance of neurotransmitter pools, trophic support, metabolism, synaptic formation and plasticity, myelin sheath formation, injury healing, and immune surveillance. They are key in regulating neurometabolic and neurovascular couplings, thereby linking neuronal activity to brain energy consumption. In particular, astrocytes respond to neuronal activity by taking up glutamate at the synapse, which triggers aerobic glycolysis and lactate secretion. Then, lactate can be used by neurons as preferred energy source upon activity, as formulated by the astrocyte-neuron lactate shuttle (ANLS) model. Astrocytes also modulate activity-dependent vasodilation through nitric oxide-mediated pathways.

3In this review, we discuss the different roles played by astrocytes in the control of brain energy metabolism and homeostasis, and how these pathways are affected in aging and hypometabolic neurodegenerative diseases such as AD. Further, we review the current therapeutic strategies from in vitro, in vivo, and clinical evidence that aim at restoring brain energy deficits in neuropathologies with metabolic dysfunctions.

Astrocyte-Mediated Metabolic Support

4Under normal homeostatic conditions, the supply and demand of energy are tightly coupled. For instance, cerebral blood flow (CBF) and glucose utilization increase in response to neuronal activity through processes known as neurovascular and neurometabolic couplings. These processes constitute the bases of functional brain imaging techniques, among which positron emission tomography (PET) that allows determination of CBF, cerebral metabolic rate of glucose consumption (CMRglc), cerebral metabolic rate of oxygen consumption CMRO2, as well as functional magnetic resonance imaging (fMRI) that measures brain oxygenation and blood volume.

5Astrocytes have unique cytoarchitectural features that ideally position them to sense their surrounding environment and dynamically respond to extracellular changes. They possess numerous processes that form highly organized anatomical domains interconnected through functional networks via gap junctions. Some of these processes closely ensheath synapses, whereas others are in contact with brain capillaries. At the synapse level, astrocytes’ perisynaptic processes express glutamate transporters that can sense changes in neuronal activity, while at the vasculature level, luminal surface of their endfeet that is in contact with vascular endothelium express glucose transporter 1 (GLUT1), that will allow facilitated diffusion of glucose into astrocytes, to supply energy upon neuronal activity. Finally, astrocytes can release vasoactive substances to act on brain glucose supply depending on neuronal activity state.

6Neurons and astrocytes possess distinct metabolic profiles. In the presence of oxygen, neurons process glucose in an oxidative way to yield ATP through mitochondrial activity, while glucose entering astrocytes preferentially undergoes glycolysis to produce pyruvate and lactate. Astrocytes specifically express glycolytic enzymes, which make them utilize 80% of the glucose through glycolysis. In neurons, glycolytic enzymes, such as 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and pyruvate dehydrogenase kinase 4 (PDK4) are inhibited, which make them highly phosphorylative cells. Furthermore, astrocytes preferentially express lactate dehydrogenase 5 (LDH5), which favors the conversion of pyruvate into lactate, while neurons exclusively express lactate dehydrogenase 1 (LDH1) that favors conversion of lactate into pyruvate. Astrocytes also have higher NADH to NAD+ ratio than neurons, which favors the reduction of pyruvate into lactate. Interestingly, inhibiting mitochondrial activity specifically in astrocytes did not have any phenotypic effect in mice. In contrast, enhancing glycolysis in neurons led to dramatic decrease in glucose utilization in the pentose phosphate pathway, increased oxidative stress and apoptosis. These studies highlight the cellular specificity of distinct metabolic pathways in the brain with astrocytes being predominantly glycolytic, while neurons are oxidative.

7As formulated by the ANLS, glutamate is taken up by astrocytes and recycled through the glutamate-glutamine cycle. This process, which is mediated by astrocytic Na+-dependent glutamate transporters, leads to increases in cytosolic Na+ that activates Na+/K+ ATPase, thereby increasing ATP consumption and stimulation of GLUT1 activity. In turn, glycolysis is activated and results in enhanced glucose uptake in astrocytes and release of lactate toward neurons. Under resting conditions, astrocytes release 85% of the glucose they consume in the form of lactate. An in vivo study using two photon microscopy and lactate fluorescence resonance energy transfer (FRET) nanosensors confirmed lactate gradient between astrocytes and neurons. Another level of astrocyte-neuron metabolic coupling is through the activity-dependent production of NH4+ in neurons that, upon transfer to astrocytes, favors astrocytic glycolysis. Thus, in neurons, conversion of glutamine into glutamate by phosphate activated glutaminase (PAG) leads to the production of NH4+, which can be transferred to astrocytes through transporters and K+ channels. In astrocytes, NH4+ can enter the mitochondria and acidifies mitochondrial matrix, which in turn inhibits mitochondrial incorporation of pyruvate that depends on the H+-coupled mitochondrial pyruvate carrier (MPC).

8Lactate is a metabolic end-product that cannot directly be used and requires its conversion into pyruvate to serve as energy and carbon source to the tricarboxylic acid (TCA) cycle. One of the advantages of producing lactate that is not readily consumed is to allow its distribution and exchanges between lactate producing and lactate consuming cells. Importantly, lactate also serves as a signaling molecule that modulates mechanisms underlying synaptic plasticity and memory consolidation through the regulation of plasticity genes expression. Neuroprotective effects of lactate have been demonstrated in various types of brain damages, including ischemic, excitotoxic and mechanical insults. The transfer of lactate between cells is specific and controlled by monocarboxylate transporters (MCTs). There are different types of MCTs that are differentially expressed between producing and receiving cells and have different affinities for lactate. For instance, neurons exclusively express high-affinity MCT2, while astrocytes express lower-affinity MCT1 and MCT4. Some studies shown that MCT2 expression in neurons is co-localized with glutamate receptors at the postsynaptic membranes of fast acting excitatory synapses, further supporting the intracellular signaling roles of lactate. Since lactate is co-transported through MCTs with H+, regulation of pH is essential for the transport of lactate. Lactate symbiosis between astrocytes and neurons is also well demonstrated through the role of energy sensor AMP-activated protein kinase (AMPK). Thus, intracerebral levels of lactate were found to be decreased in AMPK-deficient mice, which was concomitant with decreased glycolysis, oxidative phosphorylation and neuronal survival. Mechanistically, phosphorylation of AMPK in astrocytes was found to destabilize thioredoxin-interaction protein (TXNIP), which led to the translocation of GLUT1 at the plasma membrane, glucose uptake and lactate production that in turn provided neuroprotection in a non-cell-autonomous manner. The lactate signaling may also occur through the activation of the lactate responsive-G-protein-coupled receptor 81 (GPR81). Activation of GPR81 triggers Gi-mediated pathway that in turn inhibits Adenylate cyclase (AC), resulting in a decrease in cyclic AMP (cAMP) levels and changes in numerous intracellular mechanisms.

9In a key study by, transfer of lactate from astrocytes to neurons was found to be critical to mediate synaptic plasticity and memory consolidation. Pharmacological inhibition or genetic targeting of MCT2 irreversibly impairs long-term memory in mice. Long-term memory impairment could be reversed in MCT4-deficient mice by intrahippocampal administration of lactate, but not glucose. These results indicate that the neuronal uptake of lactate is important for the establishment of long-term memories. Further, degradation of glycogen, which, in the brain, is exclusively localized in astrocytes, is required for memory formation. Interestingly, exercise-mediated lactate increase was shown to enhance lactate levels in the hippocampus and to be beneficial for memory in mice. Activation of astrocytic, but not neuronal, β2-adrenergic receptors led to lactate production that mediated memory formation. Furthermore, lactate mediates neuroprotective effects following traumatic brain injury (TBI), hypoxia, cerebral ischemia, and glutamate-mediated excitotoxicity and was found to promote adult hippocampal neurogenesis. Interestingly, lactate has a dual impact on NMDA receptors. With low glutamate, lactate stimulates NMDA receptor signaling, resulting in plasticity gene induction and memory consolidation. However, in excitotoxic conditions with high glutamate, lactate decreases NMDA receptor-mediated signaling, thereby preventing glutamate-induced neuronal death. Recent evidence in vivo indicates that lactate is preferred to glucose as an energy substrate in active neurons, and that lactate metabolism shapes neuronal activity through KATP channels. An important study finally showed that the effect of circulating glucose on neuronal depolarization was exclusively mediated by astrocyte-mediated lactate release, providing strong evidence for the role of ANLS in vivo.

Brain Energy Metabolic Dysfunctions in Aging and Neurodegenerative Diseases

10Aging leads to many physiological changes in body functioning, including cerebral and cognitive functions such as decreased working, spatial and episodic memory. With age, aerobic glycolysis and consumption of glucose were found to be severely decreased in the brain, particularly in the temporal, parietal and frontal lobes, and motor cortex. This is accompanied in normal aging by the degeneration of brain structures, leading to loss in brain weight and volume, cortical thickness in the prefrontal cortex, medial temporal lobe and hippocampus, gray matter atrophy, disruptions of white matter integrity, and synaptic density. These non-pathological changes contribute to age-related cognitive decline in elderly subjects.

11Advances in neuroimaging techniques, such as MRI and PET allow to investigate the dynamic brain changes with aging in vivo. For instance, brain network connectome, which is assessed through diffusion MRI tractography efficiency, was found to decline with age in specific brain regions such as the hippocampus, thalamus, and frontal and parietal cortices. Glucose hypometabolism was observed with aging in the anterior cingulate cortex, several parts of the orbital and frontal gyrus and in the thalamus. By combining these two measurements, the study revealed a close coupling between age-dependent decreased brain network connectome and hypometabolism in specific brain regions that include frontal and temporal lobes, cingulate gyrus, hippocampus and hypothalamus. Importantly, several studies showed that glucose hypometabolism is due to a decrease of brain aerobic glycolysis as measured by the difference between glucose and oxygen consumptions. Both animal models and human studies showed that aging is characterized by a decreased aerobic glycolysis in astrocytes and mitochondrial oxidative phosphorylation in neurons. It has been proposed that pathological neurons first exhibit mitochondrial dysfunction and compensatory increase in oxidative phosphorylation that results in a competition for a limited energetic resource, i.e., astrocyte-derived lactate, as the fuel of oxidative phosphorylation. This competition for energetic resource leads to deleterious consequences on initially healthy neurons in the vicinity of neurons with mitochondrial dysfunction, thereby spreading neurodegeneration and development of the pathological state, from normal aging to neurodegeneration. At the cellular level, impaired glucose uptake is correlated with a decrease in the expression and membrane translocation of the insulin-sensitive neuronal glucose transporters, GLUT3 and GLUT4, which influence neuronal survival in the rat brain. Decrease of microvascular endothelium GLUT1 was also observed in the hypometabolic rat brain. The disruption in glucose metabolism due to the loss of glucose transporters is closely associated with synaptic dysfunction and renders neurons vulnerable to degeneration.

12Alzheimer’s disease, the most prevalent cause of age-associated dementia, is a progressive neurodegenerative disease with biochemical, metabolic and physiological changes that impact memory, thinking and behavior. In addition to the historical description of the pathology that include β amyloid plaques and hyperphosphorylated tau in the brain, it is characterized by clear mitochondrial and metabolic impairments. Hence, AD can be considered as a metabolic disease with impairment in mitochondrial bioenergetics, as well as glucose brain import and metabolism. Brain glucose hypometabolism appears early in the genesis of the pathology and is frequently present before the onset of clinically measurable symptoms. For instance, numerous studies have highlighted reduced regional activity-dependent glucose uptake and utilization in AD using 18F-fluorodeoxyglucose (FDG) PET. These decreases are mostly observed in the parieto-temporal and posterior cingulate cortices and extended to the frontal areas while disease advances, whereas primary motor and visual cortices are less severely affected, and cerebellum, thalamus and basal ganglia are relatively spared. In AD, degeneration occurs in the locus coeruleus (LC) depending on the disease progression. Noradrenaline (NA), which is released from the LC, activates cellular response in astrocytes that trigger increase in Ca2+ and cAMP, resulting in numerous cellular responses including enhanced aerobic glycolysis. Therefore, early destruction of the LC may contribute, at least in part, to the impaired glucose metabolism in AD. Another study reported a reduction of several glycolysis intermediates in the cerebrospinal fluid (CSF) of AD patients compared with controls. In postmortem AD brains, dysregulation of nutrient transporters was observed, with a decrease of neuronal GLUT3 and astrocytic GLUT1. A similar reduction in GLUT1 and lactate transporters has been reported in culture of astrocytes from AD mouse model. Postmortem studies of AD brains also revealed alterations in glycolytic enzymes activity, glucose utilization and amino acid metabolism. Several genes involved in energy regulation were downregulated in AD patients and mouse model of AD. AD symptoms essentially never occur without glucose hypometabolism, and the extent of these metabolic changes are strongly correlated with the severity of clinical symptoms. Of relevance, mitochondrial dysfunction, which is associated with age-related neurodegeneration, is also particularly important in AD. In line with the decreased glycolysis in AD brains, an interesting recent study showed that levels of lactate were reduced in the CSF of patients with AD, although no correlation were found between CSF lactate and amyloid levels. Recently, physical exercise was found to have beneficial effects in AD through the improvement of brain glucose metabolism. Thus, aerobic exercise leads to the maintenance of brain glucose uptake in mild AD patients, and to the protection against hypometabolism in brain regions particularly vulnerable in AD.

13In humans, Apolipoprotein E (APOE) exists in three different isoforms: APOE2, APOE3 and APOE4. Homozygous and heterozygous carriers of APOE4 have respectively 12 fold and 2–3 fold times increased risk of developing late-stage AD than APOE2 or 3 carriers. Depending on the ethnicity, 10–25% of the population is carrier of APOE4, which makes it the most prevalent genetic risk factor for AD. APOE4 has been clearly linked to brain hypometabolism, which was shown to precede neurodegeneration by years in APOE4(+) patients. APOE is a major cholesterol carrier involved in lipid metabolism. In the brain, APOE is primarily produced by astrocytes and regulates lipids delivery to neurons that are necessary for their structural maintenance, as well as injury repair. In conditions of stress or injury, APOE can also be expressed by neurons. Several studies have shown strong association between APOE4, metabolic genes expression and cerebral glucose uptake in human brains. Mouse models carrying the APOE4 human allele also have reduced metabolic gene expression and cerebral glucose uptake compared to APOE3 expressing models. At the cellular level, APOE4-expressing astrocytes exhibit altered glycolysis, glucose uptake and lactate secretion. Interestingly, lactate transferred from astrocytes to neurons is used for the synthesis of lipid droplets in neurons, which in turn are transported back to astrocytes through carriers that include fatty acid transport proteins (FATPs) and apolipoproteins neurodegeneration. Expression of APOE4 impairs this transport of lipid droplets between neurons and astrocytes, which in turn promotes neurodegeneration.

14Brain insulin resistance is also believed to contribute to metabolic dysfunctions in AD. Thus, a growing body of epidemiological and molecular evidence indicates an overlap in risk, comorbidity, and pathophysiological mechanisms across Type 2 diabetes (T2D), mild cognitive impairment (MCI), AD and other types of dementia such as vascular dementia, Lewy body dementia (LBD) and FTD. Studies also indicate that T2D patients are at increased risk of developing MCI or AD. While insulin resistance is a central feature of T2D, research from the past few years has also shown that it is present in the brains of patients with dementia, even in the absence of T2D. Moreover, cerebral levels of insulin and insulin receptor (IR) are lower in the brain of AD patients, and evidence for insulin signaling impairment in post-mortem brain tissue of AD patients and in animal models of AD has been shown. Insulin and insulin-like growth factors (IGFs) regulate key neuronal functions such as survival, energy metabolism and synaptic plasticity. Interestingly, insulin-mediated signaling pathways are impacted by APOE4 through the reduction of the expression of insulin receptor substrate 1 (IRS1) and Akt pathway in both mouse models and human brain tissue, and the sequestration of IR in endosomes in an age-dependent manner.

15Human and animal studies have shown that dysregulation of insulin function contributes to aging and to the development of neurodegenerative diseases. In this context, impaired glucose utilization, mitochondrial dysfunction, reduced ATP production, and energy shortage in AD led to the hypothesis that these abnormalities could be mediated, at least in part, by desensitization of IR in the brain. Several preclinical studies have highlighted the impact of insulin dysregulation in models of cognition. In mice, intracerebroventricular injection of streptozotocin was found to reduce brain glucose metabolism, mitochondrial function, IR activity and spatial learning and memory. Experimental induction of brain insulin resistance and insulin deficiency in mice causes AD-like neurodegeneration and cognitive impairment. In the brain, both neurons and astrocytes are impacted by insulin signaling. In neurons, insulin signaling modulates the expression of GABA, NMDA and AMPA receptors, catecholamine release, and glucose uptake via GLUT3. In astrocytes, insulin enhances glycogen storage, stimulates glucose uptake via GLUT1 and modulates inflammatory response. Interestingly, activation of insulin-mediated pathways was downregulated in astrocytes in response to elevated chronic insulin levels, but not in neurons. These cellular differences could have implications in the effects of T2D and insulin resistance on the function of different brain cell types.

16In AD brains, reactive astrocytes are preferentially located in the vicinity of amyloid plaques, where they exhibit abnormal morphology. In the early stage of the disease, activated astrocytes have neuroprotective action by internalizing and degrading amyloid plaques, while upon progression of the disease, deposit of amyloid plaques leads to astrocytic death that in turn contribute to further development of the pathology. Regarding the consequences of hypometabolic state in the brain, a study showed that amyloid plaques impair glucose uptake by interfering with exocytosis-dependent GLUT3 membrane expression. Several reports have described some adaptations of the astrocytic metabolism to amyloid plaques in vitro, with alterations of glycolysis and mitochondrial activity and the activation of several intracellular cascades leading to inflammation, oxidative stress and calcium dysregulation.

Insulin Signaling

17Considering the hypometabolic state and the emerging consideration of insulin signaling in AD, a number of therapeutic strategies targeting insulin-mediated pathways have been considered in order to restore brain energy metabolism. These approaches include the use of insulin sensitizer agents or intranasal insulin to restore insulin signaling in AD, as well as antidiabetic drugs such as Metformin and Glucagon-like peptide-1 receptor (GLP-1R) agonists.

18First, intranasal insulin has been developed with the objective to efficiently deliver insulin directly into the brain without changing peripheral levels that could cause insulin resistance. Insulin has been known for many years to positively modulate brain glucose utilization. In animal models of AD, intranasal insulin was found to reduce cerebral oxidative stress, tau phosphorylation and amyloid load, and improves cognitive functions (see Table 1). In humans, intranasal insulin has shown promising clinical data in MCI and AD (see Table 2). For instance, a pilot trial reported improvement of cognition in healthy volunteers after intranasal insulin administration. A subsequent study confirmed positive effect of intranasal insulin in patients with MCI or mild AD. Further study on over 100 patients with MCI or mild to moderate AD reported some preservation of cognition and function, and higher cerebral glucose utilization assessed by FDG PET, although no changes were observed in AD biomarkers. These results led to the establishment of a larger Phase 2 and 3 studies that have enrolled nearly 300 people with MCI or early-stage AD. In this trial, treatment with intranasal insulin showed positive impact on primary outcome ADAS-Cog12 memory assessment at 12 and 18 months in a patient’s cohort that has used one of the two devices used for insulin delivery, while another patient’s cohort that has used another delivery device failed to benefit from the treatment. Other series of clinical studies have evaluated long-acting insulin analog Detemir and showed that treatment of 50 MCI or AD patients led to memory improvement in APOE4 carriers, but worsened memory in non-carriers. Another study showed that insulin, but not long-acting analog Detemir, increased memory and preserved volume in several brain regions. A small trial examining the effect of the rapid acting insulin analog Glulisine in patients with MCI or middle-stage AD failed to show any acute impact in cognition. Nasal insulin has also been tested in other neurodegenerative diseases, showing for example improved clinical outcome in PD severity.

Glucagon-Like Peptide-1 Receptor Agonists

19Another therapeutic strategy aiming at restoring brain metabolism by targeting insulin-related pathway is the use of Glucagon-Like Peptide-1 Receptor (GLP-1R) agonists. GLP-1 is an incretin hormone derived from proglucagon and secreted by the small intestine in response to food intake. GLP-1R is expressed in pancreatic β-cells, kidney, heart, and CNS. Activation of GLP-1R leads to insulin release by β-cells, which in turn stimulates glucose uptake. While GLP-1 is well known for its action in the regulation of peripheral metabolism, it was also shown to play key roles in CNS functions. For instance, GLP-1 is secreted by neurons in the nucleus tractus solitarius (NTS), which results in anorexic effect and transmit vagal motor information to the pancreas. Other studies showed that overexpression of GLP-1R in the rat hippocampus improves learning, memory and neuroprotection, while transgenic mice lacking GLP-1R have deficits in learning, synaptic plasticity and cognition. Interestingly, effects of GLP-1 on energy balance were found to be mediated by astrocytes. Thus, large number of astrocytes in the NTS respond to GLP-1R agonists by intracellular calcium and cAMP signaling, while blocking NTS astrocytes activity attenuated GLP-1R agonist effects on food intake in rats. These data suggest that astrocytes play a role in the effects of GLP-1 in the brain.

20Preclinical and clinical evidence indicate therapeutic potential for some of the GLP-1R agonists that are commonly used for the treatment of diabetes and obesity (see Tables 1, 2, respectively). They include Liraglutide (Novo Nordisk), Semaglutide (Novo Nordisk) and Exendin-4, also known as Exenatide (AstraZeneca). First, in rodent models of AD, the GLP-1 analog Liraglutide was shown to promote neuronal survival, increase synaptic function, reduce neuroinflammation, amyloid plaque and hyperphosphorylated Tau, and support learning and memory. In non-human primates, Liraglutide improved insulin signaling, reduced inflammation and restored synapse number that were caused by the cortical injections of β amyloid. Interestingly, a recent study using mouse model of AD showed that Liraglutide has a specific impact on astrocytes. Treatment of AD mouse-derived astrocytes with Liraglutide resulted in a neuroprotective action and restored defective metabolic pathways, including lactate secretion. Liraglutide also showed positive effects in preclinical models of other neurological diseases, including PD, stroke and TBI. The other GLP-1R agonist Exendin-4 also exhibited neuroprotective effects in a mouse model of AD and PD.

21In humans, a pilot study has first tested the effects of 6-month Liraglutide treatment in 38 patients with AD. Liraglutide led to a clear increase in brain glucose utilization, as revealed by FDG PET. Another pilot trial was done with Liraglutide on 41 middle- to late-aged individuals with elevated blood glucose or diabetes and cognitive complaints. Primary outcome, which included fMRI before and after treatment, revealed improved connectivity within the default mode network (DMN), a system that is defective in AD. A study in 40 obese subjects with pre-diabetes or newly diagnosed T2D treated for 3 weeks with Liraglutide indicated an increase in short term memory. Most recent Phase IIb study (ELAD study) on 204 patients with mild AD and no diabetes failed to see benefit of Liraglutide on primary outcome of FDG PET, but revealed improved in cognition, as well as temporal lobe and total brain gray matter volumes. Semaglutide, another GLP-1R agonist, is set to be tested in two large Phase 3 studies (EVOKE and EVOKE Plus; NCT04777396 and NCT04777409). These trials each plan to enroll 1’840 patients with MCI or middle-stage dementia for a duration of 2 years. The clinical protocol is based on the post hoc data analyses from three clinical studies on T2D showing a 53% reduced risk of developing dementia in people who received Semaglutide or Liraglutide. Liraglutide, Semaglutide and Exendin-4 are also all currently being tested in clinical studies for PD.

Metformin

22Repositioning of Metformin, one of the most used medication for the treatment of T2D, has been another strategy to improve brain energy deficits in neurodegenerative diseases. Metformin acts through the activation of AMPK, an important regulator of glucose homeostasis. Activation of AMPK decreases gluconeogenesis, lowers blood glucose and restores insulin sensitivity. Metformin has been shown to reduce inflammation and oxidative stress, and to promote neurogenesis. Interestingly, pleiotropic effects of Metformin have been hypothesized to be mediated, at least in part, by the increased circulating concentrations of lactate produced by AMPK-mediated glucose uptake, and its use as a direct energy source in various organs. In this context, Metformin was found to directly enhance glycolysis and production of lactate by astrocytes in the brain. Metformin was found to have positive impact in cognition in high fat diet mouse models, but others found no effect of Metformin in a rat model of high fat diet-induced cognitive deficit. In a mouse model of AD, Metformin attenuated Tau aggregates and amyloid load by ameliorating microglial autophagy (Table 1). Interestingly, Metformin was found to repress the expression of Thioredoxin-interacting protein (Txnip), an inhibitor of Thioredoxin, through AMPK-mediated pathway. Repression of Txnip, which has been shown to improve glucose utilization and uptake, is postulated to participate, at least in part, in the effects of Metformin on glucose metabolism.

23In humans, several clinical studies have been assessing the impact of Metformin in MCI and AD (Table 2). First, a pilot study in 80 overweight non-diabetic people with MCI indicated that administration of Metformin for a duration of 1 year led to better performance on the Selective Reminding Test (SRT) of memory, but did not change other outcomes including ADAs-Cog, glucose uptake and plasma amyloid levels. A smaller trial in 20 non-diabetic people with MCI or AD showed that Metformin improved executive functions, led to a trend toward better learning and memory, but did not change AD biomarkers. However, contrasting study showed that long-term use of Metformin could also increase the risk of developing AD, presumably through its effect on Vitamin B12 deficiency, which is a cause of dementia. A multicentric Phase 2/3 trial that investigates the effect of Metformin on memory of 370 overweight or obese people with MCI is currently ongoing (NCT04098666). Interestingly, clinical meta-analyses showed that cognitive impairment, as well as dementia incidence, were significantly reduced in diabetic patients that were treated with Metformin.

Ketogenic Diet

24Ketogenesis is a physiological mechanism whereby ketone bodies (acetoacetate, β-hydroxybutyrate and acetone) are produced by the liver in response to fasting, exercise or reduced carbohydrate availability. Ketone bodies that are released in the circulation can be used by extra-hepatic tissues as alternative energy sources. In the mitochondria of energy-consuming cells, ketone bodies are converted in acetyl-CoA and incorporated in the TCA cycle. The brain can adapt to the utilization of ketone bodies for up to 70% of its energy requirements. In humans, the classical ketogenic diet (KD) consists in a 4 to 1 ratio of fats to proteins and carbohydrates, which physiologically mimics the fasting state and leads to hepatic ketogenesis. Although safe and efficiently enhancing levels of circulating ketone bodies, KD usually lacks long-term adherence. Alternative diets consist in the less strict Modified Atkins Diet (MAD) or supplementation to the normal diet with exogenous ketogenic agents such as medium-chain triglycerides (MCTs).

25Ketogenic diet is commonly used for the treatment of refractory epilepsy, and has been proposed as a therapeutic strategy to restore energy deficit in neuropathologies with metabolic dysfunction. Interestingly, transport of ketone bodies is directly affected by ketogenic diet through the upregulation of MCT1 and GLUT1 in the brain. Preclinical evidence showed promising results for the neuroprotective properties of KD (Table 1). For instance, KD in mice improved mitochondrial function, decreased oxidative stress, and increased ATP cerebral concentrations. In several transgenic mouse models of AD, KD was found to improve glycolysis, mitochondrial function and cognition, while reducing oxidative stress and amyloid deposition. KD also improved metabolism, mitochondrial activity and motor functions in mouse models of PD and ALS.

26In humans, the impact of KD in neurodegenerative diseases has been tested in different clinical settings (Table 2). First, pilot study showed that 12-week KD in MCI or early-stage AD patients led to non-significant trend of memory improvement. In a group of 23 patients with MCI, low carbohydrate diet was found to improve learning and memory performance compared to high carbohydrate diet. In a pilot study on 14 participants with MCI in PD, 8-week long KD enhanced cognitive performance. A larger multicentric study with 152 AD patients showed that 12-week-long administration of MCT Ketasyn/AC-1202 (Cerecin), improved memory performance in APOE4, but not in APOE4(+) patients. Another pilot study showed that treatment with MCTs in APOE4 AD patients for 30 days improved memory performance. However, no significant differences were observed in subsequent trial on 413 AD patients after 26-week long intervention with MCT Tricaprilin/AC-1204 (Cerecin). Despite these contrasting results, Phase 3 trial with Cerecin’s MCT AC-SD-03/CER-0001 has been registered and plans to enroll 300 people with mild to moderate AD that exhibit decreased FDG PET signal and have APOE4 genotype (NCT04187547). Finally, a clinical study that assessed the metabolic effect of MCT-based regimen kMCT-ONS (Nestlé Health Science) in 52 people with MCI reported increase in plasma and brain ketones, while brain glucose uptake did not differ. A larger 6-month trial in 122 MCI patients showed that treatment with kMCT-ONS diet led to improvements in memory tests, executive function and language.

Conclusion

27Brain hypometabolism is one of the first homeostatic dysregulation that occurs in age-related neurodegenerative diseases. Aging, APOE4 and insulin resistance are among the key factors that lead to brain hypometabolism. Hypometabolic changes are characterized by decreases in brain glucose uptake, expression of glucose transporters, astrocytic aerobic glycolysis, lactate release, neuronal mitochondrial function and increased oxidative stress (Figure 1). This homeostatic imbalance results in an energy gap, which renders neurons more vulnerable to a variety of insults and also decreases network connectivity. While brain hypometabolism occurs in physiological aging, it represents a significant contributing factor to a number of neurodegenerative diseases such as AD, ALS, depression, multiple sclerosis, migraine, epilepsy, TBI, retinal degeneration, stroke, or spinal cord injury (SCI).

28To target brain hypometabolism, several different therapeutic approaches that have shown promising results are presented in this review. For instance, intranasal insulin, which increases brain glucose uptake, was shown to improve cognition in AD and MCI patients. GLP-1R agonists and Metformin also improved glucose utilization and cognitive function in AD mouse models and patients. Ketogenic diet, another therapeutic strategy that aims at providing alternative source of energy to neurons, improves metabolic functions and cognition in preclinical models and human AD and MCI patients. These approaches have shown promising results, but lack selectivity to brain pathways. More targeted metabolic approaches constitute future avenues of development to tackle hypometabolic neurological diseases. Among these innovative approaches, our strategy at GliaPharm aims at specifically improving aerobic glycolysis in astrocytes, which results in the activation of the ANLS, increase in brain glucose uptake and release of lactate that is used by neurons as preferential energy source. This approach led to promising results in the impact on brain energy metabolism and neuroprotection in vitro and in different preclinical models.

29The increasing amount of evidence linking brain aging, neurological diseases and hypometabolism has therefore opened avenue for innovative therapeutic strategies, either through non-specific drug repurposing or targeted approaches to improve brain metabolism. These approaches could have disease-modifying impact in the management of the brain energy crisis in a number of neurological diseases.

Author Contributions

30All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication.

Conflict of Interest

31EB, SL, SD, and CF were employed by company GliaPharm SA. PM is an advisor for GliaPharm SA.

Publisher’s Note

32All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 280

1.
Abbas T. Faivre E. Holscher C. (2009 ). Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer’s disease. Behav. Brain Res. 205 265–271.
Not in our library10.1016/j.bbr.2009.06.035
2.
Acosta C. Anderson H. D. Anderson C. M. (2017 ). Astrocyte dysfunction in Alzheimer disease. J. Neurosci. Res. 95 2430–2447.
Not in our library10.1002/jnr.24075
3.
Ahmed K. Tunaru S. Offermanns S. (2009 ). GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol. Sci. 30 557–562.
Not in our library10.1016/j.tips.2009.09.001
4.
Ahmed K. Tunaru S. Tang C. Muller M. Gille A. Sassmann A. (2010 ). An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab. 11 311–319.
Not in our library10.1016/j.cmet.2010.02.012
5.
Ait-Ali N. Fridlich R. Millet-Puel G. Clerin E. Delalande F. Jaillard C. (2015 ). Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell 161 817–832.
Not in our library10.1016/j.cell.2015.03.023
6.
Alata W. Ye Y. St-Amour I. Vandal M. Calon F. (2015 ). Human apolipoprotein E varepsilon4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J. Cereb. Blood Flow Metab. 35 86–94.
Not in our library10.1038/jcbfm.2014.172
7.
Allaman I. Gavillet M. Belanger M. Laroche T. Viertl D. Lashuel H. A. (2010 ). Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J. Neurosci. 30 3326–3338.
Not in our library10.1523/jneurosci.5098-09.2010
8.
Allard J. S. Perez E. J. Fukui K. Carpenter P. Ingram D. K. De Cabo R. (2016 ). Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav. Brain Res. 301 1–9.
Not in our library10.1016/j.bbr.2015.12.012
9.
Alle H. Roth A. Geiger J. R. (2009 ). Energy-efficient action potentials in hippocampal mossy fibers. Science 325 1405–1408.
Not in our library10.1126/science.1174331
10.
Alvarez Z. Castano O. Castells A. A. Mateos-Timoneda M. A. Planell J. A. Engel E. (2014 ). Neurogenesis and vascularization of the damaged brain using a lactate-releasing biomimetic scaffold. Biomaterials 35 4769–4781.
Not in our library10.1016/j.biomaterials.2014.02.051
11.
Early neurone loss in Alzheimer’s disease: cortical or subcortical? · 2015
No notice
12.
Arnold S. E. Arvanitakis Z. Macauley-Rambach S. L. Koenig A. M. Wang H. Y. Ahima R. S. (2018 ). Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat. Rev. Neurol. 14 168–181.
Not in our library10.1038/nrneurol.2017.185
13.
Attwell D. Laughlin S. B. (2001 ). An energy budget for signaling in the grey matter of the brain. J. Cereb. Blood Flow Metab. 21 1133–1145.
Not in our library10.1097/00004647-200110000-00001
14.
Babetto E. Wong K. M. Beirowski B. (2020 ). A glycolytic shift in Schwann cells supports injured axons. Nat. Neurosci. 23 1215–1228.
Not in our library10.1038/s41593-020-0689-4
15.
Badawi G. A. Abd El Fattah M. A. Zaki H. F. El Sayed M. I. (2017 ). Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease. Inflammopharmacology 25 369–382.
Not in our library10.1007/s10787-017-0331-6
16.
Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury · 2020
Not checked
17.
Bak L. K. Schousboe A. Waagepetersen H. S. (2006 ). The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J. Neurochem. 98 641–653.
Not in our library10.1111/j.1471-4159.2006.03913.x
18.
Barone E. Tramutola A. Triani F. Calcagnini S. Di Domenico F. Ripoli C. (2019 ). Biliverdin reductase-a mediates the beneficial effects of intranasal insulin in Alzheimer disease. Mol. Neurobiol. 56 2922–2943.
Not in our library10.1007/s12035-018-1231-5
19.
Barros L. F. San Martin A. Ruminot I. Sandoval P. Y. Baeza-Lehnert F. Arce-Molina R. (2020 ). Fluid brain glycolysis: limits, speed, location, moonlighting, and the fates of glycogen and lactate. Neurochem. Res. 45 1328–1334.
Not in our library10.1007/s11064-020-03005-2
20.
The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease · 2018
No notice
21.
Beal M. F. (2005 ). Oxidative damage as an early marker of Alzheimer’s disease and mild cognitive impairment. Neurobiol. Aging 26 585–586.
Not in our library10.1016/j.neurobiolaging.2004.09.022
22.
Beckett T. L. Studzinski C. M. Keller J. N. Paul Murphy M. Niedowicz D. M. (2013 ). A ketogenic diet improves motor performance but does not affect beta-amyloid levels in a mouse model of Alzheimer’s disease. Brain Res. 1505 61–67.
Not in our library10.1016/j.brainres.2013.01.046
23.
Belanger M. Allaman I. Magistretti P. J. (2011 ). Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 14 724–738.
Not in our library10.1016/j.cmet.2011.08.016
24.
Belloy M. E. Napolioni V. Greicius M. D. (2019 ). A quarter century of APOE and Alzheimer’s disease: progress to date and the path forward. Neuron 101 820–838.
Not in our library10.1016/j.neuron.2019.01.056
25.
Bender A. R. Prindle J. J. Brandmaier A. M. Raz N. (2016 ). White matter and memory in healthy adults: coupled changes over two years. Neuroimage 131 193–204.
Not in our library10.1016/j.neuroimage.2015.10.085
26.
Benedict C. Hallschmid M. Hatke A. Schultes B. Fehm H. L. Born J. (2004 ). Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29 1326–1334.
Not in our library10.1016/j.psyneuen.2004.04.003
27.
Benedict C. Hallschmid M. Schmitz K. Schultes B. Ratter F. Fehm H. L. (2007 ). Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32 239–243.
Not in our library10.1038/sj.npp.1301193
28.
Bergau N. Maul S. Rujescu D. Simm A. Navarrete Santos A. (2019 ). Reduction of glycolysis intermediate concentrations in the cerebrospinal fluid of Alzheimer’s disease patients. Front. Neurosci. 13:871.
Not in our library10.3389/fnins.2019.00871
29.
Bergersen L. Waerhaug O. Helm J. Thomas M. Laake P. Davies A. J. (2001 ). A novel postsynaptic density protein: the monocarboxylate transporter MCT2 is co-localized with delta-glutamate receptors in postsynaptic densities of parallel fiber-Purkinje cell synapses. Exp. Brain Res. 136 523–534.
Not in our library10.1007/s002210000600
30.
Bergersen L. H. Magistretti P. J. Pellerin L. (2005 ). Selective postsynaptic co-localization of MCT2 with AMPA receptor GluR2/3 subunits at excitatory synapses exhibiting AMPA receptor trafficking. Cereb. Cortex 15 361–370.
Not in our library10.1093/cercor/bhh138
31.
Berthet C. Castillo X. Magistretti P. J. Hirt L. (2012 ). New evidence of neuroprotection by lactate after transient focal cerebral ischaemia: extended benefit after intracerebroventricular injection and efficacy of intravenous administration. Cerebrovasc. Dis. 34 329–335.
Not in our library10.1159/000343657
32.
Berthet C. Lei H. Thevenet J. Gruetter R. Magistretti P. J. Hirt L. (2009 ). Neuroprotective role of lactate after cerebral ischemia. J. Cereb. Blood Flow Metab. 29 1780–1789.
Not in our library10.1038/jcbfm.2009.97
33.
Bertilsson G. Patrone C. Zachrisson O. Andersson A. Dannaeus K. Heidrich J. (2008 ). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J. Neurosci. Res. 86 326–338.
Not in our library10.1002/jnr.21483
34.
Bharath L. P. Agrawal M. Mccambridge G. Nicholas D. A. Hasturk H. Liu J. (2020 ). Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. Cell Metab. 32 44–55.e6.
Not in our library10.1016/j.cmet.2020.04.015
35.
Bi Q. Wang W. Niu N. Li H. Wang Y. Huang W. (2021 ). Relationship between the disrupted topological efficiency of the structural brain connectome and glucose hypometabolism in normal aging. Neuroimage 226:117591.
Not in our library10.1016/j.neuroimage.2020.117591
36.
Bingham E. M. Hopkins D. Smith D. Pernet A. Hallett W. Reed L. (2002 ). The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 51 3384–3390.
Not in our library10.2337/diabetes.51.12.3384
37.
Bittar P. G. Charnay Y. Pellerin L. Bouras C. Magistretti P. J. (1996 ). Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J. Cereb. Blood Flow Metab. 16 1079–1089.
Not in our library10.1097/00004647-199611000-00001
38.
Bliss T. M. Ip M. Cheng E. Minami M. Pellerin L. Magistretti P. (2004 ). Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics. J. Neurosci. 24 6202–6208.
Not in our library10.1523/jneurosci.0805-04.2004
39.
Bolanos J. P. Peuchen S. Heales S. J. Land J. M. Clark J. B. (1994 ). Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J. Neurochem. 63 910–916.
Not in our library10.1046/j.1471-4159.1994.63030910.x
40.
Bonomi C. G. De Lucia V. Mascolo A. P. Assogna M. Motta C. Scaricamazza E. (2021 ). Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. Neurobiol. Aging 105 333–339.
Not in our library10.1016/j.neurobiolaging.2021.05.011
41.
Bonvento G. Sibson N. Pellerin L. (2002 ). Does glutamate image your thoughts? Trends Neurosci. 25 359–364.
Not in our library10.1016/s0166-2236(02)02168-9
42.
Born J. Lange T. Kern W. Mcgregor G. P. Bickel U. Fehm H. L. (2002 ). Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5 514–516.
Not in our library10.1038/nn849
43.
Bosshart P. D. Kalbermatter D. Bonetti S. Fotiadis D. (2019 ). Mechanistic basis of L-lactate transport in the SLC16 solute carrier family. Nat. Commun. 10:2649.
Not in our library10.1038/s41467-019-10566-6
44.
Boumezbeur F. Mason G. F. De Graaf R. A. Behar K. L. Cline G. W. Shulman G. I. (2010 ). Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 30 211–221.
Not in our library10.1038/jcbfm.2009.197
45.
Brandt J. Buchholz A. Henry-Barron B. Vizthum D. Avramopoulos D. Cervenka M. C. (2019 ). Preliminary report on the feasibility and efficacy of the modified atkins diet for treatment of mild cognitive impairment and early Alzheimer’s disease. J. Alzheimers Dis. 68 969–981.
Not in our library10.3233/jad-180995
46.
Brooks G. A. (2018 ). The science and translation of lactate shuttle theory. Cell Metab. 27 757–785.
Not in our library10.1016/j.cmet.2018.03.008
47.
Bu G. (2009 ). Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10 333–344.
Not in our library10.1038/nrn2620
48.
Burda J. E. Bernstein A. M. Sofroniew M. V. (2016 ). Astrocyte roles in traumatic brain injury. Exp Neurol 275(Pt 3) 305–315.
Not in our library10.1016/j.expneurol.2015.03.020
49.
Butterfield D. A. Halliwell B. (2019 ). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 20 148–160.
Not in our library10.1038/s41583-019-0132-6
50.
Campbell J. M. Stephenson M. D. De Courten B. Chapman I. Bellman S. M. Aromataris E. (2018 ). Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J. Alzheimers Dis. 65 1225–1236.
Not in our library10.3233/jad-180263
51.
Carbonell F. Zijdenbos A. P. Mclaren D. G. Iturria-Medina Y. Bedell B. J., Alzheimer’s Disease Neuroimaging Initiative. (2016 ). Modulation of glucose metabolism and metabolic connectivity by beta-amyloid. J. Cereb. Blood Flow Metab. 36 2058–2071.
Not in our library10.1177/0271678x16654492
52.
Carter S. F. Chiotis K. Nordberg A. Rodriguez-Vieitez E. (2019 ). Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 46 348–356.
Not in our library10.1007/s00259-018-4217-7
53.
Carteron L. Solari D. Patet C. Quintard H. Miroz J. P. Bloch J. (2018 ). Hypertonic lactate to improve cerebral perfusion and glucose availability after acute brain injury. Crit. Care Med. 46 1649–1655.
Not in our library10.1097/ccm.0000000000003274
54.
Chai T. F. Hong S. Y. He H. Zheng L. Hagen T. Luo Y. (2012 ). A potential mechanism of metformin-mediated regulation of glucose homeostasis: inhibition of Thioredoxin-interacting protein (Txnip) gene expression. Cell Signal. 24 1700–1705.
Not in our library10.1016/j.cellsig.2012.04.017
55.
Chan-Palay V. Asan E. (1989 ). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J. Comp. Neurol. 287 373–392.
Not in our library10.1002/cne.902870308
56.
Chen S. Sun J. Zhao G. Guo A. Chen Y. Fu R. (2017 ). Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP/PS1/Tau triple transgenic mice. Neurochem. Res. 42 2326–2335.
Not in our library10.1007/s11064-017-2250-8
57.
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice · 2021
Not checked
58.
Chin-Hsiao T. (2019 ). Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis. 10 37–48.
Not in our library10.14336/ad.2017.1202
59.
Chiu S. L. Chen C. M. Cline H. T. (2008 ). Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron 58 708–719.
Not in our library10.1016/j.neuron.2008.04.014
60.
Chowdhury G. M. Jiang L. Rothman D. L. Behar K. L. (2014 ). The contribution of ketone bodies to basal and activity-dependent neuronal oxidation in vivo. J. Cereb. Blood Flow Metab. 34 1233–1242.
Not in our library10.1038/jcbfm.2014.77
61.
Clarke D. W. Boyd F. T. Jr. Kappy M. S. Raizada M. K. (1984 ). Insulin binds to specific receptors and stimulates 2-deoxy-D-glucose uptake in cultured glial cells from rat brain. J. Biol. Chem. 259 11672–11675.
Not in our library
62.
Claxton A. Baker L. D. Wilkinson C. W. Trittschuh E. H. Chapman D. Watson G. S. (2013 ). Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer’s disease. J. Alzheimers Dis. 35 789–797.
Not in our library10.3233/jad-122308
63.
Hypometabolism as a therapeutic target in Alzheimer's disease · 2008
No notice
64.
Craft S. Baker L. D. Montine T. J. Minoshima S. Watson G. S. Claxton A. (2012 ). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69 29–38.
Not in our library10.1001/archneurol.2011.233
65.
Craft S. Claxton A. Baker L. D. Hanson A. J. Cholerton B. Trittschuh E. H. (2017 ). Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial. J. Alzheimers Dis. 57 1325–1334.
Not in our library10.3233/jad-161256
66.
Craft S. Raman R. Chow T. W. Rafii M. S. Sun C. K. Rissman R. A. (2020 ). Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 77 1099–1109.
Not in our library10.1001/jamaneurol.2020.1840
67.
Craft S. Watson G. S. (2004 ). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3 169–178.
Not in our library10.1016/s1474-4422(04)00681-7
68.
Cui Q. N. Stein L. M. Fortin S. M. Hayes M. R. (2021 ). The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br. J. Pharmacol.
Not in our library10.1111/bph.15683
69.
Cunnane S. Nugent S. Roy M. Courchesne-Loyer A. Croteau E. Tremblay S. (2011 ). Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition 27 3–20.
Not in our library10.1016/j.nut.2010.07.021
70.
Cureton E. L. Kwan R. O. Dozier K. C. Sadjadi J. Pal J. D. Victorino G. P. (2010 ). A different view of lactate in trauma patients: protecting the injured brain. J. Surg. Res. 159 468–473.
Not in our library10.1016/j.jss.2009.04.020
71.
Ketogenic Diet and Epilepsy: What We Know So Far · 2019
No notice
72.
De Felice F. G. Vieira M. N. Bomfim T. R. Decker H. Velasco P. T. Lambert M. P. (2009 ). Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U.S.A. 106 1971–1976.
Not in our library10.1073/pnas.0809158106
73.
de la Monte S. M. (2009 ). Insulin resistance and Alzheimer’s disease. BMB Rep. 42 475–481.
Not in our library10.5483/bmbrep.2009.42.8.475
74.
de la Monte S. M. Wands J. R. (2006 ). Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease. J. Alzheimers Dis. 9 167–181.
Not in our library10.3233/jad-2006-9209
75.
de la Torre J. C. (2008 ). Pathophysiology of neuronal energy crisis in Alzheimer’s disease. Neurodegener. Dis. 5 126–132.
Not in our library10.1159/000113681
76.
de Melo I. S. Pacheco A. L. D. Dos Santos Y. M. O. Figueiredo L. M. Nicacio D. Cardoso-Sousa L. (2021 ). Modulation of glucose availability and effects of hypo- and hyperglycemia on status epilepticus: what we do not know yet? Mol. Neurobiol. 58 505–519.
Not in our library10.1007/s12035-020-02133-8
77.
De Strooper B. Karran E. (2016 ). The cellular phase of Alzheimer’s disease. Cell 164 603–615.
Not in our library10.1016/j.cell.2015.12.056
78.
Dekaban A. S. (1978 ). Changes in brain weights during the span of human life: relation of brain weights to body heights and body weights. Ann. Neurol. 4 345–356.
Not in our library10.1002/ana.410040410
79.
Demetrius L. A. Driver J. (2013 ). Alzheimer’s as a metabolic disease. Biogerontology 14 641–649.
Not in our library10.1007/s10522-013-9479-7
80.
Demetrius L. A. Driver J. A. (2015 ). Preventing Alzheimer’s disease by means of natural selection. J. R. Soc. Interface 12:20140919.
Not in our library10.1098/rsif.2014.0919
81.
Demetrius L. A. Magistretti P. J. Pellerin L. (2014 ). Alzheimer’s disease: the amyloid hypothesis and the inverse warburg effect. Front Physiol. 5:522.
Not in our library10.3389/fphys.2014.00522
82.
Dewsbury L. S. Lim C. K. Steiner G. Z. (2021 ). The efficacy of ketogenic therapies in the clinical management of people with neurodegenerative disease: a systematic review. Adv. Nutr. 12 1571–1593.
Not in our library10.1093/advances/nmaa180
83.
Dong J. H. Wang Y. J. Cui M. Wang X. J. Zheng W. S. Ma M. L. (2017 ). Adaptive activation of a stress response pathway improves learning and memory through gs and beta-arrestin-1-regulated lactate metabolism. Biol. Psychiatry 81 654–670.
Not in our library10.1016/j.biopsych.2016.09.025
84.
Dougherty R. J. Schultz S. A. Kirby T. K. Boots E. A. Oh J. M. Edwards D. (2017 ). Moderate physical activity is associated with cerebral glucose metabolism in adults at risk for Alzheimer’s disease. J. Alzheimers Dis. 58 1089–1097.
Not in our library10.3233/jad-161067
85.
Duelli R. Schrock H. Kuschinsky W. Hoyer S. (1994 ). Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int. J. Dev. Neurosci. 12 737–743.
Not in our library10.1016/0736-5748(94)90053-1
86.
During M. J. Cao L. Zuzga D. S. Francis J. S. Fitzsimons H. L. Jiao X. (2003 ). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9 1173–1179.
Not in our library10.1038/nm919
87.
Eakin K. Li Y. Chiang Y. H. Hoffer B. J. Rosenheim H. Greig N. H. (2013 ). Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One 8:e82016.
Not in our library10.1371/journal.pone.0082016
88.
Egefjord L. Gejl M. Moller A. Braendgaard H. Gottrup H. Antropova O. (2012 ). Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer’s disease - protocol for a controlled, randomized double-blinded trial. Dan. Med. J. 59:A4519.
Not in our library
89.
El Hayek L. Khalifeh M. Zibara V. Abi Assaad R. Emmanuel N. Karnib N. (2019 ). Lactate mediates the effects of exercise on learning and memory through SIRT1-dependent activation of hippocampal brain-derived neurotrophic factor (BDNF). J. Neurosci. 39 2369–2382.
Not in our library10.1523/jneurosci.1661-18.2019
90.
El Khoury N. B. Gratuze M. Papon M. A. Bretteville A. Planel E. (2014 ). Insulin dysfunction and Tau pathology. Front. Cell Neurosci. 8:22.
Not in our library10.3389/fncel.2014.00022
91.
Farrer L. A. Cupples L. A. Haines J. L. Hyman B. Kukull W. A. Mayeux R. (1997 ). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278 1349–1356.
Not in our library
92.
Femminella G. D. Edison P. (2014 ). Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging. Alzheimers Dement. 10 S55–S61.
Not in our library10.1016/j.jalz.2013.12.012
93.
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study) · 2019
Corrected
94.
Ferreira I. L. Resende R. Ferreiro E. Rego A. C. Pereira C. F. (2010 ). Multiple defects in energy metabolism in Alzheimer’s disease. Curr. Drug Targets 11 1193–1206.
Not in our library10.2174/1389450111007011193
95.
Figley C. R. Stroman P. W. (2011 ). The role(s) of astrocytes and astrocyte activity in neurometabolism, neurovascular coupling, and the production of functional neuroimaging signals. Eur. J. Neurosci. 33 577–588.
Not in our library10.1111/j.1460-9568.2010.07584.x
96.
Fortier M. Castellano C. A. Croteau E. Langlois F. Bocti C. St-Pierre V. (2019 ). A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 15 625–634.
Not in our library10.1016/j.jalz.2018.12.017
97.
Fortier M. Castellano C. A. St-Pierre V. Myette-Cote E. Langlois F. Roy M. (2021 ). A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement. 17 543–552.
Not in our library10.1002/alz.12206
98.
Fox N. C. Schott J. M. (2004 ). Imaging cerebral atrophy: normal ageing to Alzheimer’s disease. Lancet 363 392–394.
Not in our library10.1016/s0140-6736(04)15441-x
99.
Friedland R. P. Brun A. Budinger T. F. (1985 ). Pathological and positron emission tomographic correlations in Alzheimer’s disease. Lancet 1:228.
Not in our library10.1016/s0140-6736(85)92074-4
100.
Fu W. Jhamandas J. H. (2014 ). Role of astrocytic glycolytic metabolism in Alzheimer’s disease pathogenesis. Biogerontology 15 579–586.
Not in our library10.1007/s10522-014-9525-0
101.
Gao V. Suzuki A. Magistretti P. J. Lengacher S. Pollonini G. Steinman M. Q. (2016 ). Astrocytic beta2-adrenergic receptors mediate hippocampal long-term memory consolidation. Proc. Natl. Acad. Sci. U.S.A. 113 8526–8531.
Not in our library10.1073/pnas.1605063113
102.
In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial · 2016
No notice
103.
Giaccari A. Solini A. Frontoni S. Del Prato S. (2021 ). Metformin benefits: another example for alternative energy substrate mechanism? Diabetes Care 44 647–654.
Not in our library10.2337/dc20-1964
104.
Glisky E. L. (2007 ). “Changes in cognitive function in human aging,” in Brain Aging: Models, Methods, and Mechanisms, ed. Riddle D. R. (Boca Raton, FL: CRC Press).
Not in our library
105.
Gong G. Rosa-Neto P. Carbonell F. Chen Z. J. He Y. Evans A. C. (2009 ). Age- and gender-related differences in the cortical anatomical network. J. Neurosci. 29 15684–15693.
Not in our library10.1523/jneurosci.2308-09.2009
106.
Goyal M. S. Vlassenko A. G. Blazey T. M. Su Y. Couture L. E. Durbin T. J. (2017 ). Loss of brain aerobic glycolysis in normal human aging. Cell Metab. 26 353–360.e3.
Not in our library10.1016/j.cmet.2017.07.010
107.
Gross E. C. Lisicki M. Fischer D. Sandor P. S. Schoenen J. (2019 ). The metabolic face of migraine - from pathophysiology to treatment. Nat. Rev. Neurol. 15 627–643.
Not in our library10.1038/s41582-019-0255-4
108.
Hansen H. H. Barkholt P. Fabricius K. Jelsing J. Terwel D. Pyke C. (2016a ). The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 1634 158–170.
Not in our library10.1016/j.brainres.2015.12.052
109.
Hansen H. H. Fabricius K. Barkholt P. Mikkelsen J. D. Jelsing J. Pyke C. (2016b ). Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson’s disease. Brain Res. 1646 354–365.
Not in our library10.1016/j.brainres.2016.05.038
110.
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease · 2008
No notice
111.
Harr S. D. Simonian N. A. Hyman B. T. (1995 ). Functional alterations in Alzheimer’s disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. J. Neuropathol. Exp. Neurol. 54 38–41.
Not in our library
112.
Havrankova J. Schmechel D. Roth J. Brownstein M. (1978 ). Identification of insulin in rat brain. Proc. Natl. Acad. Sci. U.S.A. 75 5737–5741.
Not in our library10.1073/pnas.75.11.5737
113.
He W. Wang H. Zhao C. Tian X. Li L. Wang H. (2020 ). Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. J. Cell Physiol. 235 2986–3001.
Not in our library10.1002/jcp.29204
114.
Henderson S. T. Morimoto B. H. Cummings J. L. Farlow M. R. Walker J. (2020 ). A placebo-controlled, parallel-group, randomized clinical trial of AC-1204 in mild-to-moderate Alzheimer’s disease. J. Alzheimers Dis. 75 547–557.
Not in our library10.3233/jad-191302
115.
Pharmacogenetic analysis of the effects of polymorphisms in <it>APOE</it>, <it>IDE </it>and <it>IL1B </it>on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study · 2011
Not checked
116.
Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial · 2009
No notice
117.
Insulin Promotes Glycogen Storage and Cell Proliferation in Primary Human Astrocytes · 2011
No notice
118.
Herrero-Mendez A. Almeida A. Fernandez E. Maestre C. Moncada S. Bolanos J. P. (2009 ). The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol. 11 747–752.
Not in our library10.1038/ncb1881
119.
Herzig S. Raemy E. Montessuit S. Veuthey J. L. Zamboni N. Westermann B. (2012 ). Identification and functional expression of the mitochondrial pyruvate carrier. Science 337 93–96.
Not in our library10.1126/science.1218530
120.
Hipkiss A. R. (2019 ). Aging, Alzheimer’s disease and dysfunctional glycolysis; similar effects of too much and too little. Aging Dis. 10 1328–1331.
Not in our library10.14336/ad.2019.0611
121.
Holscher C. (2018 ). Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology 136 251–259.
Not in our library10.1016/j.neuropharm.2018.01.040
122.
Hoyer S. (2002 ). The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural Transm. (Vienna) 109 991–1002.
Not in our library10.1007/s007020200082
123.
Hoyer S. Lee S. K. Loffler T. Schliebs R. (2000 ). Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann. N. Y. Acad. Sci. 920 256–258.
Not in our library10.1111/j.1749-6632.2000.tb06932.x
124.
Hyder F. Rothman D. L. Bennett M. R. (2013 ). Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels. Proc. Natl. Acad. Sci. U.S.A. 110 3549–3554.
Not in our library10.1073/pnas.1214912110
125.
Iadecola C. Nedergaard M. (2007 ). Glial regulation of the cerebral microvasculature. Nat. Neurosci. 10 1369–1376.
Not in our library10.1038/nn2003
126.
Imfeld P. Bodmer M. Jick S. S. Meier C. R. (2012 ). Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study. J. Am. Geriatr. Soc. 60 916–921.
Not in our library10.1111/j.1532-5415.2012.03916.x
127.
Jagust W. J. Landau S. M., and Alzheimer’s Disease Neuroimaging Initiative. (2012 ). Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J. Neurosci. 32 18227–18233.
Not in our library10.1523/jneurosci.3266-12.2012
128.
Astrocytic metabolic and inflammatory changes as a function of age · 2014
No notice
129.
Jiang T. Yin F. Yao J. Brinton R. D. Cadenas E. (2013 ). Lipoic acid restores age-associated impairment of brain energy metabolism through the modulation of Akt/JNK signaling and PGC1alpha transcriptional pathway. Aging Cell 12 1021–1031.
Not in our library10.1111/acel.12127
130.
Jourdain P. Allaman I. Rothenfusser K. Fiumelli H. Marquet P. Magistretti P. J. (2016 ). L-Lactate protects neurons against excitotoxicity: implication of an ATP-mediated signaling cascade. Sci. Rep. 6:21250.
Not in our library10.1038/srep21250
131.
Jourdain P. Rothenfusser K. Ben-Adiba C. Allaman I. Marquet P. Magistretti P. J. (2018 ). Dual action of L-Lactate on the activity of NR2B-containing NMDA receptors: from potentiation to neuroprotection. Sci. Rep. 8:13472.
Not in our library10.1038/s41598-018-31534-y
132.
Karagiannis A. Gallopin T. Lacroix A. Plaisier F. Piquet J. Geoffroy H. (2021 ). Lactate is an energy substrate for rodent cortical neurons and enhances their firing activity. Elife 10:e71424.
Not in our library10.7554/elife.71424
133.
Kashiwaya Y. Bergman C. Lee J. H. Wan R. King M. T. Mughal M. R. (2013 ). A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer’s disease. Neurobiol. Aging 34 1530–1539.
Not in our library10.1016/j.neurobiolaging.2012.11.023
134.
Keeney J. T. Ibrahimi S. Zhao L. (2015 ). Human ApoE isoforms differentially modulate glucose and amyloid metabolic pathways in female brain: evidence of the mechanism of neuroprotection by ApoE2 and implications for Alzheimer’s disease prevention and early intervention. J. Alzheimers Dis. 48 411–424.
Not in our library10.3233/jad-150348
135.
Kellar D. Craft S. (2020 ). Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 19 758–766.
Not in our library10.1016/s1474-4422(20)30231-3
136.
Kelly T. Rose C. R. (2010 ). Ammonium influx pathways into astrocytes and neurones of hippocampal slices. J. Neurochem. 115 1123–1136.
Not in our library10.1111/j.1471-4159.2010.07009.x
137.
Koenig A. M. Mechanic-Hamilton D. Xie S. X. Combs M. F. Cappola A. R. Xie L. (2017 ). Effects of the Insulin Sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis. Assoc. Disord. 31 107–113.
Not in our library10.1097/wad.0000000000000202
138.
Koss E. Friedland R. P. Ober B. A. Jagust W. J. (1985 ). Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. Am J. Psychiatry 142 638–640.
Not in our library10.1176/ajp.142.5.638
139.
Krikorian R. Shidler M. D. Dangelo K. Couch S. C. Benoit S. C. Clegg D. J. (2012 ). Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol. Aging 33 e419–e427.
Not in our library10.1016/j.neurobiolaging.2010.10.006
140.
Krikorian R. Shidler M. D. Summer S. S. Sullivan P. G. Duker A. P. Isaacson R. S. (2019 ). Nutritional ketosis for mild cognitive impairment in Parkinson’s disease: a controlled pilot trial. Clin. Park Relat. Disord. 1 41–47.
Not in our library10.1016/j.prdoa.2019.07.006
141.
Lauritzen K. H. Morland C. Puchades M. Holm-Hansen S. Hagelin E. M. Lauritzen F. (2014 ). Lactate receptor sites link neurotransmission, neurovascular coupling, and brain energy metabolism. Cereb. Cortex 24 2784–2795.
Not in our library10.1093/cercor/bht136
142.
Lee Y. Morrison B. M. Li Y. Lengacher S. Farah M. H. Hoffman P. N. (2012 ). Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487 443–448.
Not in our library10.1038/nature11314
143.
Leino R. L. Gerhart D. Z. Duelli R. Enerson B. E. Drewes L. R. (2001 ). Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem. Int. 38 519–527.
Not in our library10.1016/s0197-0186(00)00102-9
144.
Lennox R. Porter D. W. Flatt P. R. Holscher C. Irwin N. Gault V. A. (2014 ). Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology 86 22–30.
Not in our library10.1016/j.neuropharm.2014.06.026
145.
Lerchundi R. Fernandez-Moncada I. Contreras-Baeza Y. Sotelo-Hitschfeld T. Machler P. Wyss M. T. (2015 ). NH4(+) triggers the release of astrocytic lactate via mitochondrial pyruvate shunting. Proc. Natl. Acad. Sci. U.S.A. 112 11090–11095.
Not in our library10.1073/pnas.1508259112
146.
Lester-Coll N. Rivera E. J. Soscia S. J. Doiron K. Wands J. R. De La Monte S. M. (2006 ). Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J. Alzheimers Dis. 9 13–33.
Not in our library10.3233/jad-2006-9102
147.
L-Lactate Promotes Adult Hippocampal Neurogenesis · 2019
No notice
148.
Li F. Sami A. Noristani H. N. Slattery K. Qiu J. Groves T. (2020 ). Glial metabolic rewiring promotes axon regeneration and functional recovery in the central nervous system. Cell Metab. 32 767–785.e7.
Not in our library10.1016/j.cmet.2020.08.015
149.
Li Y. Duffy K. B. Ottinger M. A. Ray B. Bailey J. A. Holloway H. W. (2010 ). GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J. Alzheimers Dis. 19 1205–1219.
Not in our library10.3233/jad-2010-1314
150.
Li Y. Perry T. Kindy M. S. Harvey B. K. Tweedie D. Holloway H. W. (2009 ). GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 106 1285–1290.
Not in our library10.1073/pnas.0806720106
151.
Liang W. S. Reiman E. M. Valla J. Dunckley T. Beach T. G. Grover A. (2008 ). Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc. Natl. Acad. Sci. U.S.A. 105 4441–4446.
Not in our library10.1073/pnas.0709259105
152.
Liddelow S. A. Guttenplan K. A. Clarke L. E. Bennett F. C. Bohlen C. J. Schirmer L. (2017 ). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 481–487.
Not in our library10.1038/nature21029
153.
Lin A. L. Jahrling J. B. Zhang W. Derosa N. Bakshi V. Romero P. (2017 ). Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease. J. Cereb. Blood Flow Metab. 37 217–226.
Not in our library10.1177/0271678x15621575
154.
Liu L. Mackenzie K. R. Putluri N. Maletic-Savatic M. Bellen H. J. (2017 ). The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metab. 26:e716.
Not in our library10.1016/j.cmet.2017.08.024
155.
Liu W. Jalewa J. Sharma M. Li G. Li L. Holscher C. (2015 ). Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience 303 42–50.
Not in our library10.1016/j.neuroscience.2015.06.054
156.
Lourenco M. V. Clarke J. R. Frozza R. L. Bomfim T. R. Forny-Germano L. Batista A. F. (2013 ). TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s beta-amyloid oligomers in mice and monkeys. Cell Metab. 18 831–843.
Not in our library10.1016/j.cmet.2013.11.002
157.
Luchsinger J. A. Perez T. Chang H. Mehta P. Steffener J. Pradabhan G. (2016 ). Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J. Alzheimers Dis. 51 501–514.
Not in our library10.3233/jad-150493
158.
Machler P. Wyss M. T. Elsayed M. Stobart J. Gutierrez R. Von Faber-Castell A. (2016 ). In vivo evidence for a lactate gradient from astrocytes to neurons. Cell Metab. 23 94–102.
Not in our library10.1016/j.cmet.2015.10.010
159.
MacVicar B. A. Newman E. A. (2015 ). Astrocyte regulation of blood flow in the brain. Cold Spring Harb. Perspect. Biol. 7:a020388.
Not in our library10.1101/cshperspect.a020388
160.
Magistretti P. Allaman I. (2016 ). Bain Energy and Metabolism. New York, NY: Springer.
Not in our library
161.
Magistretti P. J. Allaman I. (2015 ). A cellular perspective on brain energy metabolism and functional imaging. Neuron 86 883–901.
Not in our library10.1016/j.neuron.2015.03.035
162.
Magistretti P. J. Allaman I. (2018 ). Lactate in the brain: from metabolic end-product to signalling molecule. Nat. Rev. Neurosci. 19 235–249.
Not in our library10.1038/nrn.2018.19
163.
Magistretti P. J. Chatton J. Y. (2005 ). Relationship between L-glutamate-regulated intracellular Na+ dynamics and ATP hydrolysis in astrocytes. J. Neural Transm. (Vienna) 112 77–85.
Not in our library10.1007/s00702-004-0171-6
164.
Magistretti P. J. Pellerin L. (1996 ). Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. Cereb. Cortex 6 50–61.
Not in our library10.1093/cercor/6.1.50
165.
Mahley R. W. Rall S. C. Jr. (2000 ). Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1 507–537.
Not in our library10.1146/annurev.genom.1.1.507
166.
Mahley R. W. Weisgraber K. H. Huang Y. (2006 ). Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 103 5644–5651.
Not in our library10.1073/pnas.0600549103
167.
Astrocyte-mediated spike-timing-dependent long-term depression modulates synaptic properties in the developing cortex. · 2020
Not checked
168.
Marcus D. L. Freedman M. L. (1997 ). Decreased brain glucose metabolism in microvessels from patients with Alzheimer’s disease. Ann. N. Y. Acad. Sci. 826 248–253.
Not in our library10.1111/j.1749-6632.1997.tb48476.x
169.
Margineanu M. B. Mahmood H. Fiumelli H. Magistretti P. J. (2018 ). L-lactate regulates the expression of synaptic plasticity and neuroprotection genes in cortical neurons: a transcriptome analysis. Front Mol Neurosci 11:375.
Not in our library10.3389/fnmol.2018.00375
170.
Masliah E. Mallory M. Hansen L. Deteresa R. Terry R. D. (1993 ). Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 43 192–197.
Not in our library10.1212/wnl.43.1_part_1.192
171.
Mathiisen T. M. Lehre K. P. Danbolt N. C. Ottersen O. P. (2010 ). The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 58 1094–1103.
Not in our library10.1002/glia.20990
172.
Mattay V. S. Fera F. Tessitore A. Hariri A. R. Berman K. F. Das S. (2006 ). Neurophysiological correlates of age-related changes in working memory capacity. Neurosci. Lett. 392 32–37.
Not in our library10.1016/j.neulet.2005.09.025
173.
McClean P. L. Jalewa J. Holscher C. (2015 ). Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. Behav. Brain Res. 293 96–106.
Not in our library10.1016/j.bbr.2015.07.024
174.
McClean P. L. Parthsarathy V. Faivre E. Holscher C. (2011 ). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J. Neurosci. 31 6587–6594.
Not in our library10.1523/jneurosci.0529-11.2011
175.
McKenna M. C. (2007 ). The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J. Neurosci. Res. 85 3347–3358.
Not in our library10.1002/jnr.21444
176.
McNeilly A. D. Williamson R. Balfour D. J. Stewart C. A. Sutherland C. (2012 ). A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. Diabetologia 55 3061–3070.
Not in our library10.1007/s00125-012-2686-y
177.
Merlini M. Meyer E. P. Ulmann-Schuler A. Nitsch R. M. (2011 ). Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol. 122 293–311.
Not in our library10.1007/s00401-011-0834-y
178.
Minoshima S. Giordani B. Berent S. Frey K. A. Foster N. L. Kuhl D. E. (1997 ). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann. Neurol. 42 85–94.
Not in our library10.1002/ana.410420114
179.
Mongeon R. Venkatachalam V. Yellen G. (2016 ). Cytosolic NADH-NAD(+) redox visualized in brain slices by two-photon fluorescence lifetime biosensor imaging. Antioxid. Redox Signal. 25 553–563.
Not in our library10.1089/ars.2015.6593
180.
Mooradian A. D. Chung H. C. Shah G. N. (1997 ). GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol. Aging 18 469–474.
Not in our library10.1016/s0197-4580(97)00111-5
181.
Moore R. Y. Bloom F. E. (1979 ). Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2 113–168.
Not in our library10.1146/annurev.ne.02.030179.000553
182.
Morland C. Lauritzen K. H. Puchades M. Holm-Hansen S. Andersson K. Gjedde A. (2015 ). The lactate receptor, G-protein-coupled receptor 81/hydroxycarboxylic acid receptor 1: expression and action in brain. J. Neurosci. Res. 93 1045–1055.
Not in our library10.1002/jnr.23593
183.
Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause? · 2020
No notice
184.
Muraleedharan R. Gawali M. V. Tiwari D. Sukumaran A. Oatman N. Anderson J. (2020 ). AMPK-regulated astrocytic lactate shuttle plays a non-cell-autonomous role in neuronal survival. Cell Rep. 32:108092.
Not in our library10.1016/j.celrep.2020.108092
185.
Nagele R. G. Wegiel J. Venkataraman V. Imaki H. Wang K. C. Wegiel J. (2004 ). Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol. Aging 25 663–674.
Not in our library10.1016/j.neurobiolaging.2004.01.007
186.
Nehlig A. (2004 ). Brain uptake and metabolism of ketone bodies in animal models. Prostaglandins Leukot. Essent. Fatty Acids 70 265–275.
Not in our library10.1016/j.plefa.2003.07.006
187.
Lactate Produced by Glycogenolysis in Astrocytes Regulates Memory Processing · 2011
No notice
188.
Novak P. Pimentel Maldonado D. A. Novak V. (2019 ). Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study. PLoS One 14:e0214364.
Not in our library10.1371/journal.pone.0214364
189.
Oberheim N. A. Takano T. Han X. He W. Lin J. H. Wang F. (2009 ). Uniquely hominid features of adult human astrocytes. J. Neurosci. 29 3276–3287.
Not in our library10.1523/jneurosci.4707-08.2009
190.
Oksanen M. Petersen A. J. Naumenko N. Puttonen K. Lehtonen S. Gubert Olive M. (2017 ). PSEN1 mutant iPSC-derived model reveals severe astrocyte pathology in Alzheimer’s disease. Stem Cell Rep. 9 1885–1897.
Not in our library10.1016/j.stemcr.2017.10.016
191.
Ong Q. R. Chan E. S. Lim M. L. Cole G. M. Wong B. S. (2014 ). Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Sci. Rep. 4:3754.
Not in our library10.1038/srep03754
192.
Owen O. E. Morgan A. P. Kemp H. G. Sullivan J. M. Herrera M. G. Cahill G. F. Jr. (1967 ). Brain metabolism during fasting. J. Clin. Invest. 46 1589–1595.
Not in our library10.1172/jci105650
193.
Palmer A. M. (1999 ). The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer’s disease. J. Neural Transm. (Vienna) 106 317–328.
Not in our library10.1007/s007020050161
194.
Ketogenic Diet in Neuromuscular and Neurodegenerative Diseases · 2014
No notice
195.
TXNIP Regulates Peripheral Glucose Metabolism in Humans · 2007
No notice
196.
Patching S. G. (2017 ). Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol. Neurobiol. 54 1046–1077.
Not in our library10.1007/s12035-015-9672-6
197.
Pawlosky R. J. Kemper M. F. Kashiwaya Y. King M. T. Mattson M. P. Veech R. L. (2017 ). Effects of a dietary ketone ester on hippocampal glycolytic and tricarboxylic acid cycle intermediates and amino acids in a 3xTgAD mouse model of Alzheimer’s disease. J. Neurochem. 141 195–207.
Not in our library10.1111/jnc.13958
198.
Pellerin L. Magistretti P. J. (1994 ). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. U.S.A. 91 10625–10629.
Not in our library10.1073/pnas.91.22.10625
199.
Pellerin L. Magistretti P. J. (2012 ). Sweet sixteen for ANLS. J. Cereb. Blood Flow Metab. 32 1152–1166.
Not in our library10.1038/jcbfm.2011.149
200.
Perry T. Greig N. H. (2005 ). Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer’s disease. Curr. Alzheimer Res. 2 377–385.
Not in our library10.2174/1567205054367892
201.
Perry T. Holloway H. W. Weerasuriya A. Mouton P. R. Duffy K. Mattison J. A. (2007 ). Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203 293–301.
Not in our library10.1016/j.expneurol.2006.09.028
202.
Peterson A. C. Li C. R. (2018 ). Noradrenergic dysfunction in Alzheimer’s and Parkinson’s diseases-an overview of imaging studies. Front. Aging Neurosci. 10:127.
Not in our library10.3389/fnagi.2018.00127
203.
Pintana H. Apaijai N. Pratchayasakul W. Chattipakorn N. Chattipakorn S. C. (2012 ). Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 91 409–414.
Not in our library10.1016/j.lfs.2012.08.017
204.
Porras O. H. Ruminot I. Loaiza A. Barros L. F. (2008 ). Na(+)-Ca(2+) cosignaling in the stimulation of the glucose transporter GLUT1 in cultured astrocytes. Glia 56 59–68.
Not in our library10.1002/glia.20589
205.
Prapong T. Buss J. Hsu W. H. Heine P. West Greenlee H. Uemura E. (2002 ). Amyloid beta-peptide decreases neuronal glucose uptake despite causing increase in GLUT3 mRNA transcription and GLUT3 translocation to the plasma membrane. Exp. Neurol. 174 253–258.
Not in our library10.1006/exnr.2001.7861
206.
Puchalska P. Crawford P. A. (2017 ). Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 25 262–284.
Not in our library10.1016/j.cmet.2016.12.022
207.
Qi L. Ke L. Liu X. Liao L. Ke S. Liu X. (2016 ). Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3beta pathway in an amyloid beta protein induced Alzheimer disease mouse model. Eur. J. Pharmacol. 783 23–32.
Not in our library10.1016/j.ejphar.2016.04.052
208.
Raber J. Huang Y. Ashford J. W. (2004 ). ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25 641–650.
Not in our library10.1016/j.neurobiolaging.2003.12.023
209.
Rachmany L. Tweedie D. Li Y. Rubovitch V. Holloway H. W. Miller J. (2013 ). Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) 35 1621–1636.
Not in our library10.1007/s11357-012-9464-0
210.
Raichle M. E. Mintun M. A. (2006 ). Brain work and brain imaging. Annu. Rev. Neurosci. 29 449–476.
Not in our library10.1146/annurev.neuro.29.051605.112819
211.
Rajkowska G. Stockmeier C. A. (2013 ). Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug Targets 14 1225–1236.
Not in our library10.2174/13894501113149990156
212.
Rasmussen P. Wyss M. T. Lundby C. (2011 ). Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans. FASEB J. 25 2865–2873.
Not in our library10.1096/fj.11-183822
213.
Reger M. A. Watson G. S. Green P. S. Baker L. D. Cholerton B. Fishel M. A. (2008a ). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimers Dis. 13 323–331.
Not in our library10.3233/jad-2008-13309
214.
Reger M. A. Watson G. S. Green P. S. Wilkinson C. W. Baker L. D. Cholerton B. (2008b ). Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 440–448.
Not in our library10.1212/01.wnl.0000265401.62434.36
215.
Reiman E. M. Chen K. Alexander G. E. Caselli R. J. Bandy D. Osborne D. (2004 ). Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc. Natl. Acad. Sci. U.S.A. 101 284–289.
Not in our library10.1073/pnas.2635903100
216.
Reiner D. J. Mietlicki-Baase E. G. Mcgrath L. E. Zimmer D. J. Bence K. K. Sousa G. L. (2016 ). Astrocytes regulate GLP-1 receptor-mediated effects on energy balance. J. Neurosci. 36 3531–3540.
Not in our library10.1523/jneurosci.3579-15.2016
217.
Resnick S. M. Pham D. L. Kraut M. A. Zonderman A. B. Davatzikos C. (2003 ). Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J. Neurosci. 23 3295–3301.
Not in our library10.1523/jneurosci.23-08-03295.2003
218.
Rivera E. J. Goldin A. Fulmer N. Tavares R. Wands J. R. De La Monte S. M. (2005 ). Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 8 247–268.
Not in our library10.3233/jad-2005-8304
219.
Riveros N. Fiedler J. Lagos N. Munoz C. Orrego F. (1986 ). Glutamate in rat brain cortex synaptic vesicles: influence of the vesicle isolation procedure. Brain Res. 386 405–408.
Not in our library10.1016/0006-8993(86)90181-2
220.
Robinson M. M. Lowe V. J. Nair K. S. (2018 ). Increased brain glucose uptake after 12 weeks of aerobic high-intensity interval training in young and older adults. J. Clin. Endocrinol. Metab. 103 221–227.
Not in our library10.1210/jc.2017-01571
221.
Rodriguez J. J. Olabarria M. Chvatal A. Verkhratsky A. (2009 ). Astroglia in dementia and Alzheimer’s disease. Cell Death Differ 16 378–385.
Not in our library10.1038/cdd.2008.172
222.
Roosterman D. Cottrell G. S. (2020 ). Astrocytes and neurons communicate via a monocarboxylic acid shuttle. AIMS Neurosci. 7 94–106.
Not in our library10.3934/neuroscience.2020007
223.
Ros J. Pecinska N. Alessandri B. Landolt H. Fillenz M. (2001 ). Lactate reduces glutamate-induced neurotoxicity in rat cortex. J. Neurosci. Res. 66 790–794.
Not in our library10.1002/jnr.10043
224.
Rosenbloom M. Barclay T. R. Kashyap B. Hage L. O’keefe L. R. Svitak A. (2021 ). A phase ii, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer’s disease. Drugs Aging 38 407–415.
Not in our library10.1007/s40266-021-00845-7
225.
The Therapeutic Potential of Metformin in Neurodegenerative Diseases · 2018
No notice
226.
Roumes H. Jolle C. Blanc J. Benkhaled I. Chatain C. P. Massot P. (2021 ). Lactate transporters in the rat barrel cortex sustain whisker-dependent BOLD fMRI signal and behavioral performance. Proc. Natl. Acad. Sci. U.S.A. 118:e2112466118.
Not in our library10.1073/pnas.2112466118
227.
Rub U. Del Tredici K. Schultz C. Thal D. R. Braak E. Braak H. (2001 ). The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer’s disease-related cytoskeletal pathology. Acta Neuropathol. 101 555–564.
Not in our library10.1007/s004010000320
228.
Saab A. S. Tzvetavona I. D. Trevisiol A. Baltan S. Dibaj P. Kusch K. (2016 ). Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism. Neuron 91 119–132.
Not in our library10.1016/j.neuron.2016.05.016
229.
Sada N. Lee S. Katsu T. Otsuki T. Inoue T. (2015 ). Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science 347 1362–1367.
Not in our library10.1126/science.aaa1299
230.
Salat D. H. Buckner R. L. Snyder A. Z. Greve D. N. Desikan R. S. Busa E. (2004 ). Thinning of the cerebral cortex in aging. Cereb. Cortex 14 721–730.
Not in our library10.1093/cercor/bhh032
231.
Samaras K. Makkar S. Crawford J. D. Kochan N. A. Wen W. Draper B. (2020 ). Metformin use is associated with slowed cognitive decline and reduced incident dementia in older adults with type 2 diabetes: the sydney memory and ageing study. Diabetes Care 43 2691–2701.
Not in our library10.2337/dc20-0892
232.
Schurr A. Payne R. S. Miller J. J. Rigor B. M. (1997 ). Glia are the main source of lactate utilized by neurons for recovery of function posthypoxia. Brain Res. 774 221–224.
Not in our library10.1016/s0006-8993(97)81708-8
233.
Schurr A. Payne R. S. Miller J. J. Tseng M. T. Rigor B. M. (2001 ). Blockade of lactate transport exacerbates delayed neuronal damage in a rat model of cerebral ischemia. Brain Res. 895 268–272.
Not in our library10.1016/s0006-8993(01)02082-0
234.
Simpson I. A. Chundu K. R. Davies-Hill T. Honer W. G. Davies P. (1994 ). Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann. Neurol. 35 546–551.
Not in our library10.1002/ana.410350507
235.
Sluggett J. K. Koponen M. Bell J. S. Taipale H. Tanskanen A. Tiihonen J. (2020 ). Metformin and risk of Alzheimer’s disease among community-dwelling people with diabetes: a national case-control study. J. Clin. Endocrinol. Metab. 105:dgz234.
Not in our library10.1210/clinem/dgz234
236.
Smith D. Pernet A. Hallett W. A. Bingham E. Marsden P. K. Amiel S. A. (2003 ). Lactate: a preferred fuel for human brain metabolism in vivo. J. Cereb. Blood Flow Metab. 23 658–664.
Not in our library10.1097/01.wcb.0000063991.19746.11
237.
Sowell E. R. Peterson B. S. Thompson P. M. Welcome S. E. Henkenius A. L. Toga A. W. (2003 ). Mapping cortical change across the human life span. Nat. Neurosci. 6 309–315.
Not in our library10.1038/nn1008
238.
Steen E. Terry B. M. Rivera E. J. Cannon J. L. Neely T. R. Tavares R. (2005 ). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease–is this type 3 diabetes? J. Alzheimers Dis. 7 63–80.
Not in our library10.3233/jad-2005-7107
239.
Sullivan P. G. Rippy N. A. Dorenbos K. Concepcion R. C. Agarwal A. K. Rho J. M. (2004 ). The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann. Neurol. 55 576–580.
Not in our library10.1002/ana.20062
240.
Supplie L. M. Duking T. Campbell G. Diaz F. Moraes C. T. Gotz M. (2017 ). Respiration-deficient astrocytes survive as glycolytic cells in vivo. J. Neurosci. 37 4231–4242.
Not in our library10.1523/jneurosci.0756-16.2017
241.
Suzuki A. Stern S. A. Bozdagi O. Huntley G. W. Walker R. H. Magistretti P. J. (2011 ). Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 144 810–823.
Not in our library10.1016/j.cell.2011.02.018
242.
Talbot K. Wang H. Y. Kazi H. Han L. Y. Bakshi K. P. Stucky A. (2012 ). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122 1316–1338.
Not in our library10.1172/jci59903
243.
Tang B. L. (2020 ). Glucose, glycolysis, and neurodegenerative diseases. J. Cell. Physiol. 235 7653–7662.
Not in our library10.1002/jcp.29682
244.
Editorial: Insulin and The Brain · 2019
Not checked
245.
Thomas S. C. Alhasawi A. Appanna V. P. Auger C. Appanna V. D. (2015 ). Brain metabolism and Alzheimer’s disease: the prospect of a metabolite-based therapy. J. Nutr. Health Aging 19 58–63.
Not in our library10.1007/s12603-014-0511-7
246.
Tieu K. Perier C. Caspersen C. Teismann P. Wu D. C. Yan S. D. (2003 ). D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112 892–901.
Not in our library10.1172/jci18797
247.
Tomi M. Zhao Y. Thamotharan S. Shin B. C. Devaskar S. U. (2013 ). Early life nutrient restriction impairs blood-brain metabolic profile and neurobehavior predisposing to Alzheimer’s disease with aging. Brain Res. 1495 61–75.
Not in our library10.1016/j.brainres.2012.11.050
248.
Uemura E. Greenlee H. W. (2001 ). Amyloid beta-peptide inhibits neuronal glucose uptake by preventing exocytosis. Exp. Neurol. 170 270–276.
Not in our library10.1006/exnr.2001.7719
249.
Vadini F. Simeone P. G. Boccatonda A. Guagnano M. T. Liani R. Tripaldi R. (2020 ). Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int. J. Obes. (Lond.). 44 1254–1263.
Not in our library10.1038/s41366-020-0535-5
250.
A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease · 2005
No notice
251.
van Gijsel-Bonnello M. Baranger K. Benech P. Rivera S. Khrestchatisky M. De Reggi M. (2017 ). Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer’s disease: alleviation by pantethine. PLoS One 12:e0175369.
Not in our library10.1371/journal.pone.0175369
252.
Energy metabolism in ALS: an underappreciated opportunity? · 2018
No notice
253.
Vardjan N. Chowdhury H. H. Horvat A. Velebit J. Malnar M. Muhic M. (2018 ). Enhancement of astroglial aerobic glycolysis by extracellular lactate-mediated increase in cAMP. Front. Mol. Neurosci. 11:148.
Not in our library10.3389/fnmol.2018.00148
254.
Veech R. L. (2004 ). The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot. Essent. Fatty Acids 70 309–319.
Not in our library10.1016/j.plefa.2003.09.007
255.
Wang J. Gallagher D. Devito L. M. Cancino G. I. Tsui D. He L. (2012 ). Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11 23–35.
Not in our library10.1016/j.stem.2012.03.016
256.
Watson K. T. Wroolie T. E. Tong G. Foland-Ross L. C. Frangou S. Singh M. (2019 ). Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease. Behav. Brain Res. 356 271–278.
Not in our library10.1016/j.bbr.2018.08.006
257.
Weise C. M. Chen K. Chen Y. Kuang X. Savage C. R. Reiman E. M. (2018 ). Left lateralized cerebral glucose metabolism declines in amyloid-beta positive persons with mild cognitive impairment. Neuroimage Clin. 20 286–296.
Not in our library10.1016/j.nicl.2018.07.016
258.
Westhaus A. Blumrich E. M. Dringen R. (2017 ). The antidiabetic drug metformin stimulates glycolytic lactate production in cultured primary rat astrocytes. Neurochem. Res. 42 294–305.
Not in our library10.1007/s11064-015-1733-8
259.
Williams H. C. Farmer B. C. Piron M. A. Walsh A. E. Bruntz R. C. Gentry M. S. (2020 ). APOE alters glucose flux through central carbon pathways in astrocytes. Neurobiol. Dis. 136:104742.
Not in our library10.1016/j.nbd.2020.104742
260.
Wilson R. S. Nag S. Boyle P. A. Hizel L. P. Yu L. Buchman A. S. (2013 ). Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology 80 1202–1208.
Not in our library10.1212/wnl.0b013e3182897103
261.
Wong-Riley M. T. (1989 ). Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 12 94–101.
Not in our library10.1016/0166-2236(89)90165-3
262.
Woo B. K. Harwood D. G. Melrose R. J. Mandelkern M. A. Campa O. M. Walston A. (2010 ). Executive deficits and regional brain metabolism in Alzheimer’s disease. Int. J. Geriatr. Psychiatry 25 1150–1158.
Not in our library10.1002/gps.2452
263.
Wu L. Zhang X. Zhao L. (2018 ). Human ApoE Isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer’s disease risk reduction and early intervention. J. Neurosci. 38 6665–6681.
Not in our library10.1523/jneurosci.2262-17.2018
264.
Xu P. T. Schmechel D. Rothrock-Christian T. Burkhart D. S. Qiu H. L. Popko B. (1996 ). Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol. Dis. 3 229–245.
Not in our library10.1006/nbdi.1996.0023
265.
Xu Q. Bernardo A. Walker D. Kanegawa T. Mahley R. W. Huang Y. (2006 ). Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26 4985–4994.
Not in our library10.1523/jneurosci.5476-05.2006
266.
Xu Q. Zhang Y. Zhang X. Liu L. Zhou B. Mo R. (2020 ). Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer’s disease patients with APOE4(-/-): a double-blind, randomized, placebo-controlled crossover trial. Clin. Nutr. 39 2092–2105.
Not in our library10.1016/j.clnu.2019.10.017
267.
Metabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease · 2020
No notice
268.
Yang J. Ruchti E. Petit J. M. Jourdain P. Grenningloh G. Allaman I. (2014 ). Lactate promotes plasticity gene expression by potentiating NMDA signaling in neurons. Proc. Natl. Acad. Sci. U.S.A. 111 12228–12233.
Not in our library10.1073/pnas.1322912111
269.
Yang Y. Bender A. R. Raz N. (2015 ). Age related differences in reaction time components and diffusion properties of normal-appearing white matter in healthy adults. Neuropsychologia 66 246–258.
Not in our library10.1016/j.neuropsychologia.2014.11.020
270.
Yao J. Brinton R. D. (2011 ). Targeting mitochondrial bioenergetics for Alzheimer’s prevention and treatment. Curr. Pharm. Des. 17 3474–3479.
Not in our library10.2174/138161211798072517
271.
Yildirim Simsir I. Soyaltin U. E. Cetinkalp S. (2018 ). Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes Metab. Syndr. 12 469–475.
Not in our library10.1016/j.dsx.2018.03.002
272.
Yin F. Sancheti H. Patil I. Cadenas E. (2016 ). Energy metabolism and inflammation in brain aging and Alzheimer’s disease. Free Radic. Biol. Med. 100 108–122.
Not in our library10.1016/j.freeradbiomed.2016.04.200
273.
Yu Y. Herman P. Rothman D. L. Agarwal D. Hyder F. (2018 ). Evaluating the gray and white matter energy budgets of human brain function. J. Cereb. Blood Flow Metab. 38 1339–1353.
Not in our library10.1177/0271678x17708691
274.
Zhang J. Cao Q. Li S. Lu X. Zhao Y. Guan J. S. (2013 ). 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer’s disease via mitochondria protection mechanism. Biomaterials 34 7552–7562.
Not in our library10.1016/j.biomaterials.2013.06.043
275.
Zhao N. Liu C. C. Van Ingelgom A. J. Martens Y. A. Linares C. Knight J. A. (2017 ). Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 96 115–129.e5.
Not in our library10.1016/j.neuron.2017.09.003
276.
Zhao W. Varghese M. Vempati P. Dzhun A. Cheng A. Wang J. (2012 ). Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease. PLoS One 7:e49191.
Not in our library10.1371/journal.pone.0049191
277.
Zhao W. Q. Townsend M. (2009 ). Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer’s disease. Biochim. Biophys. Acta 1792 482–496.
Not in our library10.1016/j.bbadis.2008.10.014
278.
Zheng J. Xie Y. Ren L. Qi L. Wu L. Pan X. (2021 ). GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer’s disease. Mol. Metab. 47:101180.
Not in our library10.1016/j.molmet.2021.101180
279.
Zhou J. Liu T. Guo H. Cui H. Li P. Feng D. (2018 ). Lactate potentiates angiogenesis and neurogenesis in experimental intracerebral hemorrhage. Exp. Mol. Med. 50 1–12.
Not in our library10.1038/s12276-018-0113-2
280.
Zulfiqar S. Garg P. Nieweg K. (2019 ). Contribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain. Biol. Chem. 400 1113–1127.
Not in our library10.1515/hsz-2019-0140

Cited by papers we hold 1

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy · 2024
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.